Systemic Therapy for Metastatic Renal-Cell Carcinoma
Top Cited Papers
- 26 January 2017
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 376 (4), 354-366
- https://doi.org/10.1056/nejmra1601333
Abstract
Kidney cancers have been extensively studied, and insights from an increased understanding of tumor biology have led to increases in survival rates. Therapies aimed at tumor signaling pathways and immunotherapies have improved the outlook for patients with renal cancer.Keywords
This publication has 89 references indexed in Scilit:
- Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinomaBritish Journal of Cancer, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trialThe Lancet Oncology, 2011
- A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802Medical Oncology, 2011
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature, 2011
- Small Renal MassNew England Journal of Medicine, 2010
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006